Compare JANX & TALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JANX | TALK |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.3M | 656.0M |
| IPO Year | 2021 | N/A |
| Metric | JANX | TALK |
|---|---|---|
| Price | $13.59 | $4.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $52.45 | $5.90 |
| AVG Volume (30 Days) | 1.0M | ★ 1.7M |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,000,000.00 | N/A |
| Revenue This Year | N/A | $24.10 |
| Revenue Next Year | $235.70 | $18.15 |
| P/E Ratio | ★ N/A | $155.55 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.12 | $2.22 |
| 52 Week High | $35.34 | $5.18 |
| Indicator | JANX | TALK |
|---|---|---|
| Relative Strength Index (RSI) | 45.87 | 68.25 |
| Support Level | $13.03 | $2.52 |
| Resistance Level | $13.79 | $5.18 |
| Average True Range (ATR) | 0.50 | 0.29 |
| MACD | 0.14 | 0.07 |
| Stochastic Oscillator | 55.56 | 84.33 |
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.